Ze-Fei Jiang
Impact in
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Breast Cancer Treatment Studies 68
- Cancer Genomics and Diagnostics 10
- Oncology 99
- HER2/EGFR in Cancer Research 49
- Cancer Treatment and Pharmacology 18
- Bone health and treatments 8
- Cancer Immunotherapy and Biomarkers 7
- Cancer Cells and Metastasis 7
- Co-authors
- Shaohua Zhang (38 shared papers)Jianbin Li (32 shared papers)Zhongsheng Tong (13 shared papers)Qingyuan Zhang (15 shared papers)Binghe Xu (7 shared papers)Santai Song (22 shared papers)Li Bian (30 shared papers)Xiaojia Wang (13 shared papers)
- Journals
- Annals of Oncology (13 papers)Annals of Translational Medicine (9 papers)Frontiers in Oncology (7 papers)The Lancet Oncology (5 papers)BMC Cancer (4 papers)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Ze-Fei Jiang
183 papers receiving 9.9k citations
Ze-Fei Jiang's Hit Papers
Peers
Comparison fields: 5 of 121
- Cancer Research 4k
- Oncology 2.9k
- Pulmonary and Respiratory Medicine 1.3k
- Health Informatics 66
- Radiology, Nuclear Medicine and Imaging 543
Countries citing papers authored by Ze-Fei Jiang
This map shows the geographic impact of Ze-Fei Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ze-Fei Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ze-Fei Jiang more than expected).
Fields of papers citing papers by Ze-Fei Jiang
This network shows the impact of papers produced by Ze-Fei Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ze-Fei Jiang. The network helps show where Ze-Fei Jiang may publish in the future.
Co-authors
The 25 scholars most cited alongside Ze-Fei Jiang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 192 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Hit paper breakdown → | 2013 | 2987 |
| 2 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 Hit paper breakdown → | 2017 | 918 |
| 3 | 2017 | 469 | |
| 4 | Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 460 |
| 5 | 2010 | 436 | |
| 6 | 2019 | 276 | |
| 7 | Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study Hit paper breakdown → | 2021 | 275 |
| 8 | 2015 | 258 | |
| 9 | 2021 | 238 | |
| 10 | 2014 | 231 | |
| 11 | 2019 | 224 | |
| 12 | 2019 | 153 | |
| 13 | 2020 | 143 | |
| 14 | 2013 | 128 | |
| 15 | 2019 | 127 | |
| 16 | Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial Hit paper breakdown → | 2024 | 97 |
| 17 | 2013 | 95 | |
| 18 | 2005 | 88 | |
| 19 | 2020 | 87 | |
| 20 | 2007 | 73 |
About Ze-Fei Jiang
Ze-Fei Jiang is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Health Informatics and Pathology and Forensic Medicine, having authored 192 papers that have together received 10.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (68 papers), HER2/EGFR in Cancer Research (49 papers), Advanced Breast Cancer Therapies (25 papers), Cancer Treatment and Pharmacology (18 papers), Cancer Genomics and Diagnostics (10 papers), Bone health and treatments (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cancer Cells and Metastasis (7 papers). The work is most often cited by research in Cancer Research (4k citations), Oncology (2.9k citations), Pulmonary and Respiratory Medicine (1.3k citations), Health Informatics (66 citations) and Radiology, Nuclear Medicine and Imaging (543 citations). Ze-Fei Jiang has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Shaohua Zhang, Jianbin Li, Zhongsheng Tong, Qingyuan Zhang, Binghe Xu, Santai Song, Li Bian, Xiaojia Wang, Jifeng Feng and Shusen Wang. Their work appears in journals such as Annals of Oncology, Annals of Translational Medicine, Frontiers in Oncology, The Lancet Oncology and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.